CNSP CNS Pharmaceuticals, Inc.
Healthcare$5.37+0.00%OpenMarket Cap: $3.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
51.83
P/S
0.00
EV/EBITDA
-0.02
DCF Value
$15.50
FCF Yield
-489.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-238.7%
ROA
-354.3%
ROIC
-5485.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-5.0M | $-4.9M | $— | — |
| Q4 null | $0.00 | Infinity% | $-6.0M | $-6.0M | $— | — |
| FY null | $0.00 | NaN% | $-16.0M | $-15.9M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-3.3M | $-3.2M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-2.4M | $-2.4M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-4.3M | $-4.3M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-3.2M | $-3.2M | $— | — |
| FY null | $0.00 | -Infinity% | $-14.9M | $-14.9M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-5.6M | $-5.6M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-2.5M | $-2.5M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-3.5M | $-3.5M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-5.4M | $-5.4M | $-28,623.00 | — |